Combined with the uninformative prior distribution and data, the posterior probabilities of a greater hazard in CYP2C19 intermediate and poor metabolizers than in extensive metabolizers were 79.8 and 87.6%, respectively (Figure S2), suggesting that impaired CYP2C19 metabolizers may encounter prolonged effects by PPI, which potentially further increase the gastric cancer risk. The gene discussed is CYP2C19; the disease is gastric cancer.